PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.
US market dynamics will result in headwinds for drug manufacturers hoping to make a fast return on investment from the sale of biosimilar versions of AbbVie’s blockbuster Humira (adalimumab), industry watchers said during a panel discussion on the US biosimilars market sponsored by the IQVIA Institute on 28 February.
Economic incentives for payers and the pharmacy benefit managers (PBMs) charged with negotiating formulary placement for drugs in the US...
Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.
Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.
Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.
Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.
Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.
The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.
Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.
